The Latest Breaking News from Bristol Myers Squibb

Companies are cashing in on AI productivity gains. Some bosses think workers deserve a cut

Leaders at PepsiCo, Indeed, Dropbox, and Bristol Myers Squibb are rethinking who benefits from AI’s productivity gains.

Fortune · Oct 19

Neuroendocrine Tumor Patients Whose Lutetium Therapy Stopped Working Saw Slower Progression on Actinium-Based RYZ101 in Phase 3 Trial

Bristol Myers Squibb says actinium-based RYZ101 improved progression-free survival in neuroendocrine tumors after lutetium therapy. Topline data are company-reported.

Medical Daily · Oct 15

Bristol Myers Pulmonary Fibrosis Drug Admilparant Met Main Goal at 60 mg, but Higher Dose Missed

BMS said Admilparant met its phase 3 goal in pulmonary fibrosis at 60 mg, but 120 mg missed. Data are topline. What patients and families should know.

Medical Daily · Oct 15

Two Drugmakers Have Paused Autoimmune CAR T Cell Trials After Three Deaths from a Severe Immune Reaction

Novartis paused eight autoimmune CAR T trials after three severe immune reactions, and Bristol Myers Squibb paused enrollment in its program.

Medical Daily · Sep 2

BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing

BioNTech shares moved higher as the broader biotech sector reached a post-pandemic peak, lifted by positive late-stage cancer vaccine data from peers rather than new clinical results of its own.

Barchart · Aug 24

FDA Clears a New Class of Myeloma Drug for Patients Whose Cancer Returned After Earlier Treatment

The FDA granted accelerated approval to iberdomide, the first CELMoD for relapsed multiple myeloma, usable as early as first relapse.

Medical Daily · Aug 17

Soriot should explain the curious case of AstraZeneca’s non-deal

AstraZeneca’s rumoured takeover of Bristol Myers Squibb already looked weird, and was met with a lack of enthusiasm by shareholders

The Guardian - UK · Aug 5

AstraZeneca should stick to its winning formula. It doesn’t need a $400bn US mega-merger

The Anglo-Swedish drugmaker’s flirtation with a grand combo with US group Bristol Myers Squibb is baffling

The Guardian - UK · Aug 3

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion.

Benzinga · Aug 3

AstraZeneca in talks over £300bn mega-merger with US rival – reports

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

Evening Standard · Aug 3